CTOs on the Move

Contraline

www.contraline.com

 
Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception. The company is developing ADAM™, the world`s first injectable hydrogel designed to provide long-lasting barrier contraception for men. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Yelena Tropsha
Chief Technology Officer Profile

Similar Companies

ActiveCare

ActiveCare, Inc. provides patented diabetes and chronic disease management and wellness solutions that increase visibility, lower costs and provide real-time care for members resulting in improved outcomes. Utilizing state-of-the-art meters with embedded cellular technology, trained CareSpecialists can intervene in real-time and provide members with the support needed to control their disease 24 hours a day, every day. ActiveCare's solution is revolutionizing the way employers, individuals and their health plans monitor chronic disease.  

Arriva Medical

Arriva Medical is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContainMed

ContainMed is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Claret Medical

Claret Medical has been the leader in the field of cerebral protection since 2011, with approximately 97% market share in Europe, and is the first in the category to be commercially available in the U.S.

Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.